HK-listed HBM climbs on initiating next phase of asthma drug study
09/09/2026 03:47
BUZZ-HK-listed HBM climbs on initiating next phase of asthma drug study ** Shares of HBM Holdings 2142.HK climb 3.7% to HK$15.09
** Therapeutics developer says its partner Windward Bio AG reported positive Phase II interim results of the POLARIS-1 clinical trial of HBM9378/WIN378 in asthma, and Phase III study has also been initiated
** HBM9378/WIN378 is a novel fully human, ultra-long-acting monoclonal antibody with a unique binding mode to inhibit thymic stromal lymphopoietin
** YTD, stock up 24.6%, Hang Seng Biotech Index .HSBIO up 10.5%
(Reporting by Donny Kwok)
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study